Roche Deal Seen As Boon For Other Targeted Cancer Therapy Develop
After Roche (RHHBY) announced a definitive agreement to acquire Ignyta (RXDX), a company focused on precisely targeted cancer therapeutics guided by diagnostic tests, in a transaction valued at $1.7B, Wall Street analysts are opining on what read-through this deal may have on other smaller companies exploring similar areas of oncology. ROCHE AGREEMENT: Roche announced this…